Fig. 8

A and B Volume of subcutaneous tumors in mice of different treatment groups. C Tumor weight of subcutaneous tumors in mice of different treatment groups. D and E Area of death and Ki-67-positive cell ratio of subcutaneous tumors in the four groups of mice. F Expression levels of FASN, HIF1α, and SLC7A11 in different treatment groups as determined by IHC analysis. G Schematic illustration demonstrating that FASN binding to HIF1α facilitated the entry of HIF1α into the nucleus to promote SLC7A11 transcription thereby inhibiting ferroptosis and promoting sorafenib resistance, while orlistat reversed sorafenib resistance by inhibiting FASN expression. Scale bars, 100 μm. *p < 0.05; **p < 0.01; ***p < 0.001. sora, sorafenib; orli, orlistat; Ferro-1, ferrostatin-1